A daily price is not the same thing as a bill. That distinction matters at MANÜ Telehealth, where the homepage advertises GLP-1 treatment “from $4/day” in one place and “from $5/day” in another. Neither block establishes which medication, supply duration or payment commitment produces that starting rate. For someone budgeting for ongoing care, the central question is not which daily figure looks better, but what amount will actually be collected and when.
MANÜ documents a virtual weight-management service offering compounded injectable semaglutide and tirzepatide, with clinical review, pharmacy fulfillment and advertised follow-up support. There is useful information about package inclusions and cancellation, but not enough to reconstruct a complete treatment bill. This documentary review examines the sources consulted October 19, 2026, emphasizing payment obligations, responsible businesses and unresolved terms rather than treating promotional prices as complete quotes.
At a glance
- Advertised GLP-1 starting prices
- The homepage displays both “from $4/day” and “from $5/day,” without resolving the difference or specifying the associated product, supply or commitment.Sources: [7]
- Documented medications
- MANÜ advertises compounded injectable semaglutide and compounded injectable tirzepatide, not a documented price for a specific FDA-approved branded product.
- Package inclusions
- The homepage says each medication package includes the online consultation, medication, supplies and shipping.Sources: [7]
- Recurring payments
- Certain services recur at the fee and frequency disclosed at purchase. Subscription prices can change with advance notice.Sources: [11]
Start with the checkout amount, not the daily headline
MANÜ’s two daily starting prices are partial advertising disclosures, not interchangeable quotes. The evidence does not identify whether they reflect different medications, presentations, offers or purchasing arrangements. It also does not establish whether either is introductory or available on renewal. Converting one into a monthly estimate would add assumptions about the charged period and eligibility that the public material does not support.
The intake page does make one narrower financial promise: its initial assessment is free, takes less than five minutes and involves nothing being charged. Starting or resuming that form requires an email address and phone number. That is useful separation between the initial questionnaire and paid service, but the advertised completion time is not a promise about clinical review, prescription approval or medication delivery.
Before authorizing payment, request the medication and formulation, exact first charge, covered supply period, next charge date and renewal amount in writing. Ask whether payment is collected before clinical acceptance and what happens if treatment is not prescribed. Our guide to understanding the first GLP-1 payment explains why those details matter more than multiplying a daily promotional figure.
| Published statement | What it establishes | What remains unresolved |
|---|---|---|
| GLP-1s from $4/day | A starting promotional rate appears on the homepage | Medication, supply period, collected amount and commitment |
| GLP-1s from $5/day | A second starting rate appears on the same homepage | Why it differs from $4/day and which terms apply |
| Free initial assessment | The initial form is advertised as involving no charge | Timing and amount of a later treatment payment |
| Medication package inclusions | Consultation, medication, supplies and shipping are advertised together | Complete package price and boundaries of ongoing services |
| MIC Ultraburn starting at $150 | A separate add-on has a published starting price | Supply period, billing frequency and final charge |
What the package promises—and which extras remain unpriced
The homepage FAQ says each medication package includes the online consultation, medication, supplies and shipping. This is a meaningful inclusion statement: MANÜ does not present those four items there as separately priced line items. However, the reviewed documents do not establish whether every follow-up encounter, laboratory service or additional administrative request falls within the package. A bundled description still needs an actual package quote.
MANÜ separately markets MIC Ultraburn, an injectable blend of methionine, inositol and choline, as an add-on to GLP-1 treatment. Its plan starts at $150, but the displayed offer does not specify a supply duration or billing frequency. Descriptions of support for metabolism and energy are the provider’s promotional claims, not established outcomes from this review. That price should not be mistaken for the semaglutide or tirzepatide charge.
The broader catalog also lists NAD+, sermorelin, glutathione and Bliss Tabs under longevity and sexual-health categories. Their presence does not make them part of a GLP-1 package. The supplied evidence also does not establish insurance acceptance, medication coverage, prior-authorization assistance or HSA/FSA eligibility. Readers can use our guide to what a GLP-1 program price includes to distinguish bundled items from optional purchases and unanswered cost questions.
Recurring charges need a calendar and a renewal quote
MANÜ’s terms say certain services operate as subscriptions. Enrollment authorizes recurring charges at the applicable fee and frequency stated when purchasing. The reviewed public material does not supply a complete semaglutide or tirzepatide billing schedule. It therefore cannot establish a calendar-month subscription, a four-week cycle, a particular prepaid plan or a minimum commitment. Those are separate contract details, not conclusions that follow from a daily starting price.
The terms also allow subscription prices to change with advance notice. Continued use after the change takes effect is treated as acceptance of the new price. That is not a documented price lock. Promotional codes have their own conditions, can be restricted to particular products or services and may expire without notice. No fully specified current discount in the supplied evidence resolves the underlying first-payment or renewal questions.
A useful checkout record would show both the amount due now and the next scheduled collection, together with the services each payment covers. Ask whether a change in the prescribed presentation affects the bill; the reviewed evidence does not answer that question. Our explanation of monthly, four-week and prepaid billing helps keep payment intervals distinct without assuming that MANÜ uses any particular one.
Canceling a subscription is different from recovering a payment
For general subscriptions, MANÜ directs cancellation requests to info@manutelehealth.com. Cancellation normally becomes effective at the end of the current billing cycle unless otherwise specified. The terms say partial billing periods are not refunded unless applicable law requires it. This gives a contact route and a general stopping point, but it does not promise that ending a subscription reverses an already collected payment.
The broader refund language describes sales as final, with exceptions for company-initiated cancellation and applicable legal requirements. It says refunds generally are unavailable once services have been rendered or medication dispensed. Separately, when MANÜ cancels an order after payment, the terms promise a full refund to the original payment method and reasonable efforts to notify the customer. The reviewed evidence does not establish a bank-arrival timetable for that refund.
A separate nutrition-store section requires contact at least 48 hours before the next scheduled renewal; later requests may not prevent that cycle’s charge and shipment. Those rules control nutrition-store transactions when they conflict with the general terms. They should not automatically be applied to clinical subscriptions. Our guide to cancellation and refund boundaries explains why a request to stop future billing and a request for money back need separate answers.
Identify who is providing care and who is taking payment
The intake consent attributes healthcare services to Ziggy Telehealth LLC and describes the platform as technology only. The legal center likewise identifies Ziggy as the healthcare practice shown to patients as MANÜ Telehealth. It identifies Medoura as a technology platform owned and operated by CoFabri LLC, not a healthcare provider, medical practice, pharmacy, laboratory or emergency service. These distinctions matter when determining which organization owes a service or handles a payment dispute.
The general terms use a different description: MANÜ facilitates connections, is not a licensed medical provider and leaves medical decisions to independent licensed professionals. The team page lists Cristina, Nadja and Richard as nurse practitioners and Selvia as a family nurse practitioner. A medication page, meanwhile, describes prescribing by a board-certified physician if approved. These statements do not establish which clinician would treat a particular applicant, and their credentials were not independently verified here.
MANÜ’s legal center directs billing, refund, subscription, pharmacy and fulfillment questions to the responsible practice, merchant of record, pharmacy or other provider identified in the workflow or receipt. Before paying, obtain those names and contact details rather than relying on the brand alone. The conflicting clinical descriptions deserve clarification, but they do not establish that no clinical service exists. They make a clear receipt and assigned care contact especially important.
Resolve location and clinical acceptance before budgeting for treatment
Geographic availability is materially inconsistent. The homepage says MANÜ has licensed-provider and pharmacy coverage in all 50 states, subject to network changes and address confirmation through intake. The privacy policy, however, says services are unavailable outside Florida and tells non-Florida residents not to use them. It also excludes people outside the United States and residents of other countries. The reviewed evidence cannot reconcile the nationwide advertisement with the Florida-only restriction.
The general terms require users to be at least 18 and provide accurate, current and complete information. Both medication pages describe adults with a BMI of at least 30, or at least 27 with weight-related conditions, as their target population. These published thresholds are not individual approval. The supplied documents do not fully establish required laboratory testing, associated charges, intake exclusions or transfer requirements for people already using a GLP-1 medication.
The advertised process begins with questions about health goals and medical history, followed by clinician review, without required in-person visits. The terms say a clinician-patient relationship begins only upon the professional’s explicit acceptance and that prescriptions are not guaranteed. Obtain confirmation of service availability at your address before treating a quoted price as usable. Likewise, the free questionnaire should not be interpreted as acceptance into ongoing care or assurance of a prescription.
Pharmacy fulfillment and the limits of free shipping
MANÜ explicitly says it is not an internet pharmacy and does not dispense, ship or distribute medications from its own facility or website. Its notice says prescribed medication is dispensed exclusively through a U.S. 503A pharmacy. The privacy policy names Boudreaux, Shields Pharmacy and Hallandale as pharmacies that prepare and ship prescribed medication. Those names do not establish which pharmacy would fill a specific order, and this review did not independently verify their licenses.
The advertised delivery process involves a U.S. pharmacy filling the prescription and shipping directly to the patient with free shipping and discreet packaging. That removes a stated shipping charge, not the treatment charge. The supplied evidence establishes no definite clinical-review, preparation, dispatch or arrival timetable. It also does not define cold-chain specifications or a clinical-shipment replacement policy. Ask which pharmacy is assigned and who handles delayed, damaged or temperature-compromised deliveries.
The medications advertised are compounded injectable semaglutide and tirzepatide. FDA explains that compounded preparations are not FDA approved and lack FDA premarket review for safety, effectiveness and quality; nonapproval alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and state-licensed pharmacy. For injectable GLP-1 medication arriving warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy.
Follow-up belongs in the price discussion
MANÜ advertises continuous support, regular follow-up consultations, progress tracking and treatment-plan adjustments as needed. It also advertises 24/7 patient support. Those statements describe an ongoing service, but the supplied evidence does not define the appointment cadence, response-time target or precise financial boundaries of follow-up. Ask which encounters are included in your quoted package and whether any additional consultation, laboratory work or administrative service can generate another charge.
The legal center expressly warns that messages, intake submissions, forms and refill requests may not be reviewed immediately. The platform is not an emergency service; it directs emergencies to 911 or an emergency department and U.S. mental-health crises to 988. Around-the-clock support advertising therefore should not be read as immediate clinician access. For budgeting and continuity, ask how refills are requested and what happens if a review remains pending near the next charge.
The privacy policy says patients can request a copy or summary of their health information, usually within 30 days, potentially with a reasonable cost-based fee. That is another documented service boundary worth retaining. More broadly, NIDDK describes follow-up as attention to treatment response and tolerability, not simply renewed payments. A useful MANÜ quote should connect the payment schedule to the actual care schedule rather than leave the two as unrelated promises.
Questions & answers
What will my first MANÜ semaglutide or tirzepatide payment be?
The supplied evidence does not establish a complete first payment for either compounded injectable medication. The homepage’s $4/day and $5/day starting claims omit the associated product, supply period and payment commitment. The initial assessment is advertised as free with nothing charged. Request a written checkout quote showing the actual amount collected, what it covers and the next scheduled charge before authorizing paid service.
Does MANÜ include medication and shipping, or only a consultation?
Its homepage says each medication package includes the online consultation, medication, supplies and shipping. That is broader than a consultation-only offer. However, the reviewed evidence does not define every follow-up or laboratory expense. MIC Ultraburn is separately advertised as an add-on starting at $150, without a stated supply period or billing interval; do not assume it is included in a GLP-1 package.
Will MANÜ automatically bill me again at the same price?
Certain services have recurring billing at the fee and frequency disclosed at purchase. The public evidence does not establish the particular schedule for your medication order or a guaranteed unchanged renewal price. Subscription prices can change with advance notice, and continued use after the effective date counts as acceptance under the terms. Save the checkout disclosures and ask for the next renewal date and amount.
How do I cancel, and does the 48-hour rule apply to medication care?
The general subscription terms direct cancellation requests to info@manutelehealth.com, normally effective at the current cycle’s end, without partial-period refunds unless legally required. The explicit at-least-48-hours notice rule belongs to nutrition-store subscriptions and should not automatically be transferred to clinical care. Ask for your clinical renewal cutoff in writing. Cancellation alone does not create a refund entitlement for services already rendered or medication already dispensed.
Can I use MANÜ if I live outside Florida?
The reviewed documents do not provide a reliable yes-or-no answer. The homepage advertises all-50-state provider and pharmacy coverage, subject to address confirmation, but the privacy policy says services are restricted to Florida residents and instructs others not to use them. Obtain clarification of that conflict and confirmation for your location before proceeding. The nationwide advertisement alone does not resolve the restriction in the privacy policy.
Who should handle a MANÜ billing or medication-delivery problem?
The legal center directs these questions to the responsible practice, merchant of record, pharmacy or other provider named in your workflow or receipt. MANÜ says it does not itself dispense or ship medications, so retain the dispensing pharmacy’s contact details as well as your payment receipt. The platform warns that messages may not be reviewed immediately; its advertised 24/7 support is not a guaranteed immediate response or emergency service.
Our assessment
MANÜ documents more than a bare medication advertisement: it identifies compounded injectable offerings, describes clinical intake, names pharmacy participants and promises a package containing consultation, medication, supplies and shipping. The free initial assessment and published cancellation email are useful disclosures. Nevertheless, its cost transparency remains incomplete because neither daily starting price establishes the actual first bill, renewal charge or covered period. The conflicting geographic restrictions and descriptions of clinical responsibility also deserve resolution before payment. A practical next step is a written, itemized quote tied to your address, assigned practice, dispensing pharmacy and cancellation terms. Without that documentation, MANÜ’s public starting prices are insufficient for a dependable treatment budget.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- MANÜ Telehealth — en/start ↗
- MANÜ Telehealth — en/weight loss/semaglutide ↗
- MANÜ Telehealth — en/about ↗
- MANÜ Telehealth — en/weight loss/tirzepatide ↗
- MANÜ Telehealth — en ↗
- MANÜ Telehealth — en/patient legal ↗
- MANÜ Telehealth — en/weight loss/mic ultraburn ↗
- MANÜ Telehealth — en/privacy policy ↗
- MANÜ Telehealth — en/terms of service ↗